<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02368691</url>
  </required_header>
  <id_info>
    <org_study_id>G200901</org_study_id>
    <nct_id>NCT02368691</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)</brief_title>
  <official_title>A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GTx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GTx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if GTx-024 is effective and safe in the treatment&#xD;
      of patients with advanced, androgen receptor positive triple negative breast cancer (AR+&#xD;
      TNBC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of Efficacy&#xD;
  </why_stopped>
  <start_date type="Actual">June 2015</start_date>
  <completion_date type="Actual">September 22, 2017</completion_date>
  <primary_completion_date type="Actual">September 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects</measure>
    <time_frame>Sixteen (16) weeks</time_frame>
    <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST) as assessed by CT or MRI in subjects with centrally confirmed AR+ status. Clinical Benefit Rate=CR+PR+SD. Complete Response (CR), disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease, &lt;30% decrease in sum of the longest diameter of target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate, in Full Analysis Set</measure>
    <time_frame>Sixteen (16) weeks</time_frame>
    <description>To estimate the clinical benefit rate in all subjects who receive at least one dose of study medication (full analysis set), regardless of central confirmation of AR status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response</measure>
    <time_frame>From treatment initiation to end of treatment (up through 11 months of treatment, median duration of treatment 1.9 months).</time_frame>
    <description>To assess best overall response as measured by RECIST 1.1 from the start of study treatment until the end of treatment taking into account any requirement for confirmation. Best overall response is reported as the best response (CR, PR or SD) by CT or MRI up through 11 months of treatment, median duration of treatment 1.9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From treatment initiation to tumor progression or death. PFS was assessed up to 11 months of treatment; median duration of treatment, 1.9 months</time_frame>
    <description>To assess progression free survival (PFS) defined as the time elapsed between initiation of treatment and tumor progression as measured by RECIST 1.1 or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-progression</measure>
    <time_frame>From treatment initiation to tumor progression or death. Time to progression was assessed up to 11 months of treatment; median duration of treatment, 1.9 months</time_frame>
    <description>To assess time to progression defined as time elapsed between treatment initiation and tumor progression as measured by RECIST 1.1 or death due to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>From time of documented tumor response to tumor progression or death. Duration of response was assessed through 11 months; median treatment duration, 1.9 months</time_frame>
    <description>To assess the duration of response defined as the time from documentation of tumor response to disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Sixteen (16) weeks</time_frame>
    <description>To estimate the objective response rate (defined as complete response or partial response) according to RECIST 1.1.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to twelve (12) months</time_frame>
    <description>To describe the safety profile in subjects with TNBC and centrally confirmed AR+ as well as in all subjects enrolled and treated.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>GTx-024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GTx-024</intervention_name>
    <description>GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
    <arm_group_label>GTx-024</arm_group_label>
    <other_name>Enobosarm</other_name>
    <other_name>Ostarine</other_name>
    <other_name>S-22</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to give voluntary, written and signed, informed consent&#xD;
&#xD;
          -  Women ≥ 18 years of age&#xD;
&#xD;
          -  Women with TNBC who have received at least one but no more than two prior chemotherapy&#xD;
             regimens for TNBC&#xD;
&#xD;
          -  Confirmation of AR+ (defined as ≥ 10% nuclear AR staining by immunohistochemistry&#xD;
             [IHC]) TNBC in either the primary or metastatic lesion, assessed during the screening&#xD;
             period by a local laboratory or by medical history&#xD;
&#xD;
          -  TNBC confirmed by medical history as: human epidermal growth factor receptor 2&#xD;
             [HER2]-negative (confirmed by IHC 0, 1+ regardless of fluorescence in situ&#xD;
             hybridization [FISH] ratio; IHC 2+ with FISH ratio lower than 2.0 or HER2 gene copy&#xD;
             less than 6.0; FISH ratio of 0, indicating gene deletion, when positive and negative&#xD;
             in situ hybridization [ISH] controls are present); estrogen receptor (ER) negative&#xD;
             (confirmed as ER expression less than or equal to 1% positive tumor nuclei);&#xD;
             progesterone receptor negative (confirmed as progesterone receptor expression less&#xD;
             than or equal to 1% positive tumor nuclei)&#xD;
&#xD;
          -  Availability of paraffin embedded or formalin fixed tumor tissue; OR, a minimum of 10&#xD;
             and up to 20 slides of archived tumor tissue for central laboratory confirmation of AR&#xD;
             status and molecular subtyping. Metastatic tumor tissue is preferred when possible&#xD;
&#xD;
          -  Subjects must have either measurable disease or bone-only non-measurable disease,&#xD;
             evaluable according to RECIST 1.1&#xD;
&#xD;
          -  Subjects with bone metastases should be treated with intravenous bisphosphonates or&#xD;
             subcutaneous denosumab (or investigator preferred standard of care) prior to and&#xD;
             during the trial, unless there is a contraindication or subject intolerance to these&#xD;
             therapies&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at the time of&#xD;
             screening and enrollment&#xD;
&#xD;
          -  Negative pregnancy test in women of childbearing potential (premenopausal or less than&#xD;
             12 months of amenorrhea post-menopause, and who have not undergone surgical&#xD;
             sterilization), no more than 7 days before the first dose of study treatment&#xD;
&#xD;
          -  For women of childbearing potential who are sexually active, agreement to use a highly&#xD;
             effective, non-hormonal form of contraception during and for at least 6 months after&#xD;
             completion of study treatment; OR, a fertile male partner willing and able to use&#xD;
             effective non-hormonal of contraception (barrier method of contraception in&#xD;
             conjunction with spermicidal jelly, or surgical sterilization) during and for at least&#xD;
             6 months after completion of study treatment&#xD;
&#xD;
          -  Adequate organ function as shown by:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000 cells/mm3&#xD;
&#xD;
               -  Platelet count ≥ 100,000 cells/mm3&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5&#xD;
                  Upper Limit of the Normal range (ULN) (or ≤ 5 if hepatic metastases are present)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 2.0 × ULN (unless the subject has documented Gilbert&#xD;
                  Syndrome)&#xD;
&#xD;
               -  Alkaline phosphatase levels ≤ 2.5 × ULN (≤ 5 × ULN in subjects with liver&#xD;
                  metastasis)&#xD;
&#xD;
               -  Serum creatinine &lt; 2.0 mg/dL or 177 μmol/L&#xD;
&#xD;
               -  International normalized ratio (INR), activated partial thromboplastin time&#xD;
                  (aPTT), or partial thromboplastin time (PTT) &lt; 1.5 × ULN (unless on anticoagulant&#xD;
                  treatment at screening)&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  Any toxicity from prior chemotherapy has resolved or Grade 1 (NCI-CTCAE, Version 4.0)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt; 4 months;&#xD;
&#xD;
          -  Subjects with radiographic evidence of central nervous system (CNS) metastases as&#xD;
             assessed by computerized tomography (CT) or magnetic resonance imaging (MRI) that are&#xD;
             not well controlled (symptomatic or requiring control with continuous corticosteroid&#xD;
             therapy [e.g., dexamethasone]). Note: Subjects with CNS metastases are permitted to&#xD;
             participate in the study if the CNS metastases are medically well controlled prior to&#xD;
             screening (as assessed by the Investigator) after receiving local therapy&#xD;
             (irradiation, surgery, etc.)&#xD;
&#xD;
          -  Radiotherapy within 14 days prior to first dose of study treatment&#xD;
&#xD;
          -  Have, in the judgment of the Investigator, a clinically significant concurrent illness&#xD;
             or psychological, familial, sociological, geographical, or other concomitant condition&#xD;
             that would not permit adequate follow-up and compliance with the study protocol&#xD;
&#xD;
          -  Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at screening&#xD;
&#xD;
          -  Positive human immunodeficiency virus (HIV) infection at screening&#xD;
&#xD;
          -  Prior treatment with any anti-androgens, including but not limited to, enzalutamide&#xD;
             and bicalutamide&#xD;
&#xD;
          -  Major surgery within 28 days of the first dose of study treatment&#xD;
&#xD;
          -  Be currently taking or have previously taken testosterone, methyltestosterone,&#xD;
             oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®),&#xD;
             testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other&#xD;
             androgenic compounds, including herbals), or anti-androgens&#xD;
&#xD;
          -  Treatment with any of the following hormone replacement therapies, unless discontinued&#xD;
             at least 14 days prior to the first dose of study treatment:&#xD;
&#xD;
               -  Estrogens&#xD;
&#xD;
               -  Megesterol acetate&#xD;
&#xD;
          -  Treatment with any investigational agent within 28 days before the first dose of study&#xD;
             treatment&#xD;
&#xD;
          -  Another active cancer (excluding adequately treated basal cell carcinoma or cervical&#xD;
             intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ). Prior&#xD;
             history of other cancer is allowed as long as there is no active disease within the&#xD;
             prior 5 years&#xD;
&#xD;
          -  Subject has a concomitant medical condition that precludes adequate study treatment&#xD;
             compliance or assessment, or increases subject risk, in the opinion of the&#xD;
             Investigator, such as but not limited to:&#xD;
&#xD;
               -  Myocardial infarction or arterial thromboembolic events within 6 months prior to&#xD;
                  baseline or severe or unstable angina, New York Heart Association (NYHA) Class&#xD;
                  III or IV disease, or a QTcB (corrected according to Bazett's formula) interval &gt;&#xD;
                  470 msec; serious uncontrolled cardiac arrhythmia grade II or higher according to&#xD;
                  NYHA; uncontrolled hypertension (systolic &gt; 150 and/or diastolic &gt; 100 mm Hg)&#xD;
&#xD;
               -  Acute and chronic active infectious disorders and non-malignant medical illnesses&#xD;
                  that are uncontrolled or whose control may be jeopardized by the complications of&#xD;
                  this study therapy&#xD;
&#xD;
               -  Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
                  significantly alter the absorption of study drugs (e.g., ulcerative disease,&#xD;
                  uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)&#xD;
&#xD;
          -  Current treatment with intravenous bisphosphonate or denosumab with elevated serum&#xD;
             calcium corrected for albumin or ionized calcium levels outside institutional normal&#xD;
             limits at screening&#xD;
&#xD;
          -  History of non-compliance to medical regimens&#xD;
&#xD;
          -  Subjects unwilling to or unable to comply with the protocol procedures as assessed by&#xD;
             the Investigator&#xD;
&#xD;
          -  Concurrent participation in another therapeutic clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hope S Rugo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Health Care/Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Frontier Cancer Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic, PC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology / Texas Oncology, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2015</study_first_posted>
  <results_first_submitted>September 13, 2020</results_first_submitted>
  <results_first_submitted_qc>October 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2020</results_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 26, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/91/NCT02368691/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Up to 55 patients were planned for enrollment</recruitment_details>
      <pre_assignment_details>No patients were excluded from the study before drug assignment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GTx-024</title>
          <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32">32 subjects were enrolled and received at least one dose of study drug</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GTx-024</title>
          <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="35" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AR status-positive</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects</title>
        <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST) as assessed by CT or MRI in subjects with centrally confirmed AR+ status. Clinical Benefit Rate=CR+PR+SD. Complete Response (CR), disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease, &lt;30% decrease in sum of the longest diameter of target lesions.</description>
        <time_frame>Sixteen (16) weeks</time_frame>
        <population>Subjects who were centrally confirmed as AR+</population>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) Subjects</title>
          <description>To estimate the clinical benefit rate (defined as complete response, partial response, or stable disease) according to Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST) as assessed by CT or MRI in subjects with centrally confirmed AR+ status. Clinical Benefit Rate=CR+PR+SD. Complete Response (CR), disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Stable Disease, &lt;30% decrease in sum of the longest diameter of target lesions.</description>
          <population>Subjects who were centrally confirmed as AR+</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate, in Full Analysis Set</title>
        <description>To estimate the clinical benefit rate in all subjects who receive at least one dose of study medication (full analysis set), regardless of central confirmation of AR status.</description>
        <time_frame>Sixteen (16) weeks</time_frame>
        <population>All subjects, regardless of AR status</population>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate, in Full Analysis Set</title>
          <description>To estimate the clinical benefit rate in all subjects who receive at least one dose of study medication (full analysis set), regardless of central confirmation of AR status.</description>
          <population>All subjects, regardless of AR status</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response</title>
        <description>To assess best overall response as measured by RECIST 1.1 from the start of study treatment until the end of treatment taking into account any requirement for confirmation. Best overall response is reported as the best response (CR, PR or SD) by CT or MRI up through 11 months of treatment, median duration of treatment 1.9 months.</description>
        <time_frame>From treatment initiation to end of treatment (up through 11 months of treatment, median duration of treatment 1.9 months).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response</title>
          <description>To assess best overall response as measured by RECIST 1.1 from the start of study treatment until the end of treatment taking into account any requirement for confirmation. Best overall response is reported as the best response (CR, PR or SD) by CT or MRI up through 11 months of treatment, median duration of treatment 1.9 months.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>To assess progression free survival (PFS) defined as the time elapsed between initiation of treatment and tumor progression as measured by RECIST 1.1 or death.</description>
        <time_frame>From treatment initiation to tumor progression or death. PFS was assessed up to 11 months of treatment; median duration of treatment, 1.9 months</time_frame>
        <population>All patients regardless of AR status</population>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>To assess progression free survival (PFS) defined as the time elapsed between initiation of treatment and tumor progression as measured by RECIST 1.1 or death.</description>
          <population>All patients regardless of AR status</population>
          <units>months</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.7" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-progression</title>
        <description>To assess time to progression defined as time elapsed between treatment initiation and tumor progression as measured by RECIST 1.1 or death due to disease progression.</description>
        <time_frame>From treatment initiation to tumor progression or death. Time to progression was assessed up to 11 months of treatment; median duration of treatment, 1.9 months</time_frame>
        <population>All subjects regardless of AR status</population>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-progression</title>
          <description>To assess time to progression defined as time elapsed between treatment initiation and tumor progression as measured by RECIST 1.1 or death due to disease progression.</description>
          <population>All subjects regardless of AR status</population>
          <units>months</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.7" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>To assess the duration of response defined as the time from documentation of tumor response to disease progression or death</description>
        <time_frame>From time of documented tumor response to tumor progression or death. Duration of response was assessed through 11 months; median treatment duration, 1.9 months</time_frame>
        <population>All subjects regardless of AR status</population>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>To assess the duration of response defined as the time from documentation of tumor response to disease progression or death</description>
          <population>All subjects regardless of AR status</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.1" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate</title>
        <description>To estimate the objective response rate (defined as complete response or partial response) according to RECIST 1.1.</description>
        <time_frame>Sixteen (16) weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>To estimate the objective response rate (defined as complete response or partial response) according to RECIST 1.1.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adverse Events</title>
        <description>To describe the safety profile in subjects with TNBC and centrally confirmed AR+ as well as in all subjects enrolled and treated.</description>
        <time_frame>Up to twelve (12) months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GTx-024</title>
            <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>To describe the safety profile in subjects with TNBC and centrally confirmed AR+ as well as in all subjects enrolled and treated.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>one year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GTx-024</title>
          <description>GTx-024 capsules, 18 mg PO once-daily for up to 12 months&#xD;
GTx-024: GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE 4.0">CHF</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>tumor flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>blood disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (Unspecified)">investigations</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>metabolism</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>nervous system</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to lack of efficacy and limited data reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mary Breitmeyer</name_or_title>
      <organization>Oncternal</organization>
      <phone>858-434-1113</phone>
      <email>MBreitmeyer@oncternal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

